<DOC>
	<DOC>NCT01078545</DOC>
	<brief_summary>The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms (LUTS) in patients with diagnosed locally advanced and/or metastatic prostate cancer and LUTS.</brief_summary>
	<brief_title>Lucrin速 Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)</brief_title>
	<detailed_description>The remaining target is: - to assess the intensity of LUTS in Polish and Ukrainian patients with locally advanced and metastatic prostate cancer, previously untreated with hormonal therapy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Age &gt; 50 years Locally advanced (T3T4) and/or metastatic (N+/M+) hormonesensitive prostate cancer, confirmed by histological examination Presence of lower urinary tract symptoms (LUTS)IPSS &gt;0 Treatment with Lucrin速 Depot is the routine therapy in the patient. The decision as to Lucrin速 Depot choice will not be associated with patient's participation in the study, but will result from the best medical knowledge and practice. Until inclusion into PMOS the patient has not been treated with GnRH analogue. The patient, before inclusion into the study, has not been treated by surgery (radical prostatectomy). Patients will not be included into the study if any contraindications to treatment with Lucrin速 Depot exist, or if there are other treatment options which, according to the present medical knowledge, are potentially more beneficial for the patient. Physician or patient can stop treatment at any moment, if any indications or reasons exist.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Lower urinary tract symptoms</keyword>
	<keyword>Hormonotherapy</keyword>
	<keyword>LHRH analogue</keyword>
	<keyword>Androgen deprivation therapy (ADT)</keyword>
</DOC>